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Abstract
Background: Limited studies have examined the intestinal microbiota composition in relation to changes in disease course
of IBD over time. We aimed to study prospectively the fecal microbiota in IBD patients developing an exacerbation during
follow-up.
Design: Fecal samples from 10 Crohn’s disease (CD) and 9 ulcerative colitis (UC) patients during remission and subsequent
exacerbation were included. Active disease was determined by colonoscopy and/or fecal calprotectine levels. Exclusion
criteria were pregnancy, antibiotic use, enema use and/or medication changes between consecutive samples. The microbial
composition was assessed by 16S rDNA pyrosequencing.
Results: After quality control, 6,194–11,030 sequences per sample were available for analysis. Patient-specific shifts in
bacterial composition and diversity were observed during exacerbation compared to remission, but overarching shifts
within UC or CD were not observed. Changes in the bacterial community composition between remission and exacerbation
as assessed by Bray-Curtis dissimilarity, were significantly larger in CD versus UC patients (0.59 vs. 0.42, respectively;
p = 0.025). Thiopurine use was found to be a significant cause of clustering as shown by Principal Coordinate Analysis and
was associated with decreases in bacterial richness (Choa1 501.2 vs. 847.6 in non-users; p,0.001) and diversity (Shannon
index: 5.13 vs. 6.78, respectively; p,0.01).
Conclusion: Shifts in microbial composition in IBD patients with changing disease activity over time seem to be patient-
specific, and are more pronounced in CD than in UC patients. Furthermore, thiopurine use was found to be associated with
the microbial composition and diversity, and should be considered when studying the intestinal microbiota in relation to
disease course.
Citation: Wills ES, Jonkers DMAE, Savelkoul PH, Masclee AA, Pierik MJ, et al. (2014) Fecal Microbial Composition of Ulcerative Colitis and Crohn’s Disease Patients
in Remission and Subsequent Exacerbation. PLoS ONE 9(3): e90981. doi:10.1371/journal.pone.0090981
Editor: Jack Anthony Gilbert, Argonne National Laboratory, United States of America
Received September 8, 2013; Accepted February 5, 2014; Published March 7, 2014
Copyright:  2014 Wills et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was financially supported by grants form the Academic Foundation of Maastricht University Medical Center+ and by the IBD Research
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: MP has acted as a consultant for MSD and received payments for lectures from MSD, Falk, Pharma, Abvie and Ferring. The other authors
have declared that no competing interests exist. The authors can confirm that the competing interests that they have declared do not alter their adherence to all
PLOS ONE policies on sharing data and materials.
* E-mail: j.penders@mumc.nl
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory diseases of the gastrointestinal tract, collectively
referred to as inflammatory bowel disease (IBD). IBD is a
heterogenous disease ith respect to disease location, disease course,
occurrence of extra-intestinal manifestations and therapeutic
response. The disease course is characterized by exacerbations
and remissions. IBD is generally considered to arise from the
interaction between host genetics, environmental factors, dysreg-
ulated immune responses and alterations in the intestinal
microbiota composition [1]. IBD, especially active disease, is
associated with a decreased quality of life and high health care
costs, [2,3] especially due to the use of medication [2,4].
Treatment is mainly based on symptom reduction by nonspecific
immune-modulating drugs and can be associated with serious side
effects [5]. Further insight in causative factors associated with the
development of exacerbations (i.e. active mucosal inflammation)
may contribute to new specific treatment options for IBD.
The intestinal microbiota is considered to play a central role in
the pathogenesis of IBD and numerous studies have corroborated
evidence for intestinal dysbiosis in IBD patients compared to
healthy controls [6–9]. The gut microbiota of healthy individuals is
dominated by the bacterial phyla Firmicutes and Bacteroidetes,
and to a lesser extent by Proteobacteria, Actinobacteria and
Verrucomicrobia [10]. In IBD patients, members of the
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Firmicutes phylum appear to be reduced, [9,11,12] whereas
members of Gammaproteobacteria seem to bloom [13–16]. In CD
patients the Clostridia cluster IV group, in particular Faecalibacter-
ium prausnitzii, has shown to be decreased [15,17]. Members of
Clostridia group XIVa, belonging to the Roseburia genus, also seem
to be decreased in all IBD patients [17–19]. Data on Bacteroidetes
are more ambiguous; inconsistent findings have been reported for
their presence in IBD compared to controls [20–25]. In addition
to these differences in relative abundances of specific phylotypes,
there appears to be a general decrease in biodiversity in IBD
patients [25,26].
Altogether, these studies provide compelling evidence for
changes in the gut microbial communities in IBD patients as
compared to healthy controls. Only a few studies, however,
investigated the intestinal microbiota in relation to disease activity.
Differences in bacterial species or groups (e.g. F. prausnitzii,
Clostridia, E. coli and Fusobacterium varium) were found, when
comparing active with inactive UC and CD patients,[7,9,20,27–
29] but could not always be confirmed [17]. These studies are
prone to confounding effects due to their cross-sectional designs
and differences in medication use. Studies monitoring the
microbiota composition within patients with changing disease
activity over time and controlling for medication use are currently
lacking. Therefore, the aim of the present study was to
prospectively monitor the microbial composition in UC and CD
patients during remission and subsequent exacerbation by means
of 16S rDNA pyrosequencing.
Materials and Methods
Population and Design
The current study was conducted within the context of a
prospective follow-up cohort of IBD outpatients, in which
standardized demographic and clinical data, feces and blood
samples were collected at study entry, at every subsequent
outpatient visit and during an exacerbation [30].
The diagnosis of IBD was based on clinical and endoscopic or
radiological findings. For case definition of CD, the Lennard-Jones
criteria were applied [31]. UC was defined as continuous mucosal
inflammation with granulomata, affecting the rectum and/or some
or all of the colon in continuity with the rectum. Data of
concomitant use of medication, body mass index (BMI), disease
duration since diagnosis and disease phenotype (Montreal
classification) were obtained using the computer-based medical
registration databases. Furthermore at each visit, the occurrence of
infections was checked by medical history and culture if indicated,
and questions on overall changes in dietary habits were completed.
Fecal samples were collected at home on the evening before or
the morning of each visit and stored at 4uC. Upon arrival at the
hospital, the faecal samples were split directly. Part was sent to the
laboratory of Clinical Chemistry for routine analysis of fecal
calprotectine and the remaining part was frozen at 280uC within
24 hours after defecation for analyses of the microbiota.
Within the prospective cohort, patients with faecal samples at
remission as well as after subsequent development of an
exacerbation during a one-year follow-up period were eligible
for the present study.
As clinical indices do not correlate very well with endoscopic
scores [32,33] and as we aimed to assess the association of the fecal
microbiota with the presence of mucosal inflammation, an
exacerbation was defined by colonoscopy, a calprotectin value .
150 mg/g feces or .5-fold increase in calprotectin as compared to
remission levels. For CD, only patients with colonic involvement
were included as fecal samples are not likely to reflect microbial
composition in the small intestine. For UC, eligible patients had
pancolitis, left-sided colitis or proctosigmoiditis. Exclusion criteria
were pregnancy, use of rectal enemas, use of antibiotics in the 3
months prior to inclusion or during follow-up, and/or a change in
immunosuppressive medication between sampling at remission
and subsequent development of disease exacerbation.
Ethics Statement
The study was approved by the Medical Ethics Committee of
the Maastricht University Medical Center+ (NL31636.068.10),
and written informed consent was obtained from all subjects.
16S rRNA V1–V3 Amplicon Library Preparation
Approximately 200 milligram feces was used for DNA isolation
by the PSP SPIN Stool DNA plus kit (Stratec Molecular GmbH,
Berlin, Germany) according to the manufacturer’s instructions and
eluted in a final volume of 200 mL.
Amplicon libraries for pyrosequencing of the 16S rDNA V1–V3
regions were generated using a barcoded forward primer
consisting of the 454 Titanium platform A linker sequence (59-
CCATCCCTGCGTGTCTCCGACTCAG-39), a key (barcode)
that was unique for each sample, and the 16S rRNA 534R primer
sequence 59- ATTACCGCGGCTGCTGG -39, and a reverse
primer consisting of a 9:1 mixture of two oligonucleotides, 59-B-
AGAGTTTGATCMTGGCTCAG-39 and 59-B- AGGGTTC-
GATTCTGGCTCAG-39, where B represents the B linker (59-
CCTATCCCCTGTGTGCCTTGGCAGTCTCAG-39) followed
by the 16S rRNA 8F and 8F-Bif primers, respectively (Table S1)
[34].
PCR amplifications (in a volume of 50 mL) were performed
using 16FastStart High Fidelity Reaction Buffer, 1.8 mMMgCl2,
1 mM dNTP solution, 5 U FastStart High Fidelity Blend
Polymerase (from the High Fidelity PCR System (Roche,
Indianapolis, USA)), 0.2 mM reverse primer, 0.2 mM of the
barcoded forward primer (unique for each sample) and 1 mL of
template DNA. PCR was performed using the following cycle
conditions: an initial denaturation at 94uC for 3 min, followed by
25 cycles of denaturation at 94uC for 30 s, annealing at 51uC for
45 s and extension at 72uC for 5 min, and a final elongation step
at 72uC for 10 min. Amplicons (20 mL) were purified using
AMPure XP purification (Agencourt, Massachusetts, USA)
according to the manufacturer’s instructions and eluted in 25 ml
16 low TE (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0).
Amplicon concentrations were determined by Quant-iT Pico-
Green dsDNA reagent kit (Invitrogen, New York, USA) using a
Victor3 Multilabel Counter (Perkin Elmer, Waltham, USA).
Amplicons were mixed in equimolar concentrations to ensure
equal representation of each sample. A one-region 454 sequencing
run was performed on a GS FLX Titanium PicoTiterPlate with a
GS FLX pyrosequencing system (Roche, Branford, USA).
Data Analysis
The V1–V3 16S rDNA bacterial sequences analyzed in this
paper have been deposited in the MG-RAST database (project ID:
4728).
Raw pyrosequencing reads were initially passed through quality
filters to reduce the overall error rate using Mothur version 1.23
[35]. Only those sequences with perfect proximal primer fidelity
and a threshold quality score of $20, a read length between 200
and 540 nucleotides, a maximum of one ambiguous base call and a
maximum homopolymer length of 9 were retained for further
analysis.
Subsequent data processing was conducted using Quantitative
Insights Into Microbial Ecology (QIIME) version 1.5.1 [36].
Microbiota in Relation to Disease Course of IBD
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Barcodes were used to identify sequences belonging to each
patient sample. The UCLUST algorithm was used to cluster
sequences into operational taxonomic units (OTUs) or phylotypes
based on 97% similarity (species level) against the Greengenes
reference set [37]. The following nondefault search parameters for
UCLUST were applied: maxrejects = 100 and stepwords = 16.
Creation of new clusters for sequences that did not cluster to
reference sequences within the given similarity threshold was
disabled, to further reduce the influence of pyrosequencing errors.
Species richness and diversity within communities (alpha-
diversity) was measured by means of the observed OTUs (observed
richness), Chao1 index (estimated richness), and the Shannon
diversity index. Beta-diversity or diversity shared across patient
communities was determined by UniFrac distance and Bray-
Curtis dissimilarity (BC). UniFrac distances are based on the
fraction of branch length shared between two communities within
a phylogenetic tree constructed from the 16S rRNA gene
sequences from all communities being compared. A relatively
small UniFrac distance implies that two communities are
compositionally similar, harboring lineages sharing a common
evolutionary history [38]. Both weighted and unweighted UniFrac
were used, respectively taking into account the abundance of each
bacterial species for creating branch length or not.
Statistical Analysis
BC and Unweighted UniFrac distances were calculated for each
patient (remission versus active sample) and distances were
subsequently compared between CD and UC patients using the
Mann-Whitney U test. Distances between subsequent samples
from the same patient (within subjects) and distances between
remission samples of different patients (between subjects) were also
compared using the Mann-Whitney U test. The above mentioned
statistical analyses were conducted using SPSS version 20.
All subsequent statistical analyses were conducted within
QIIME 1.5.1, unless stated otherwise.
Age was dichotomized in two groups with 52 years (median age)
as cut-off. Differences in alpha-diversity with respect to IBD type,
disease location, age, gender and medication use (thiopurines,
TNF-a inhibitors, aminosalicylates, prednisone or methotrexate)
were tested using a nonparametric two-sample t-tests (i.e. using
Monte Carlo permutations to calculate the p-value) at a
rarefaction intensity of .6,190 sequences per sample. To test for
differences in alpha-diversity within patients with respect to disease
activity, the Wilcoxon Signed-Rank test was applied (conducted
within SPSS v. 20).
OTU coverage was estimated using the conditional uncovered
probability method [39]. Analysis of similarities (ANOSIM) was
used to test for differences in community structure (UniFrac)
among the various groups (IBD type, disease location, age, gender
and medication use) in remission state. ANOSIM is a permuta-
tion-based test of the null hypothesis that within-group distances
are not significantly smaller than between-group distances [40].
To test for associations between OTUs (presence) and IBD type,
disease location, age, gender and medication use, the G-test
statistic was used. To test for differences in the relative abundance
of OTUs, the paired-sample T-test was used with respect to
disease activity (within group comparisons) and ANOVA was used
to test for differences with respect to IBD type, disease location,
age, gender and medication use between groups. The false
discovery rate (FDR) method was used to correct for multiple
testing at a cutoff of 0.25. The relatively high value was used so as
not to miss possible associations.
Results
Study Population
Out of the 323 patients from the prospective IBD cohort, with
an average of three subsequent samples per subject, ten CD and
nine UC patients that fulfilled our criteria could be selected.
Patient characteristics are presented in Table 1. All patients,
except one, had calprotectin levels above 150 mg/g feces at time of
active disease. The single patient with a calprotectin level below
150 mg/g, showed a 9-fold increase (from 14 toward 126 mg/g
faeces) during the flare as compared to remission.
454 Sequencing
In total, 230,026,772 bases and 551,607 sequences were
recovered following pyrosequencing. After trimming, filtering
and binning 324,085 sequences (mean length 6SD: 310672.7
bases), ranging from 6,194 to 11,030 sequences per sample,
remained for downstream analysis. A total of 2,839 OTUs were
found with an OTU coverage of 97.1% 61.1% (mean 6 s.d.).
Dominant phyla across all samples included Firmicutes (81.3%),
Bacteroidetes (15.9%), Proteobacteria (3.8%), Actinobacteria
(3.7%), Verrucomicrobia (2.5%) and Tenericutes (1.1%) (Figure 1).
Patient-specific shifts in bacterial composition were observed in
all patients. In a subgroup of patients, major shifts were observed
for specific bacteria. Two CD patients (labeled #10 and 11 in
Figure 1) showed strong increases in the relative abundances of
Bacteroides fragilis during active disease, i.e. from 0.1% to 10.1%
and from 0.1% to 81.9% respectively, whereas another CD patient
(#17) showed a large increase in relative abundance of Akkermansia
muciniphila (1.6% to 62.9%) during activity. Similarly, one UC
patient (#8) showed a strong increase in the relative abundance of
Bacteroides dorei (2.6% to 18.3%) and another UC patient (#3)
showed an increase (1.2% to 13.9%) of an undefined Lactobacillus
species. Despite these shifts in the individual microbial profiles, no
significant difference in presence or relative abundance of any
particular species or group was detected based on disease activity
on a group level neither in the CD nor in the UC patients.
Furthermore, no sequences from pathogenic species such as
Campylobacter spp., Helicobacter spp., Salmonella spp. or Mycobacterium
spp. were detected.
Effects on Richness and Diversity
No significant differences in any alpha-diversity metrics were
found comparing subgroups based on IBD type, or disease activity
(Table 2), nor for disease location, age, gender or use of TNF-a
inhibitor, aminosalicylate, prednisone or methotrexate (data not
shown). Alpha-diversity seemed to be affected in only one CD
patient (#11) during follow up. This patient showed a large
relative increase of fecal B. fragilis abundance during relapse
compared to remission as reported above.
Thiopurine was used by 7 patients both at remission and during
exacerbation (median treatment duration 49.5 (2–182) months),
and was found to be associated with a lower number of observed
OTUs, Chao1 and Shannon index (Table 2). The median daily
dose expressed as 6-mercaptopurine (6-MP) equivalences [41] was
57.9 mg per day.
The number of observed OTUs in thiopurine users was
significantly decreased among IBD patients in general (p = 2.37 *
1024), but also when studying CD patients (p = 2.57*1025) and
UC patients (p = 7.93 * 1024) separately (Figure 2).
Effects on Community Membership and Composition
Unweighted UniFrac-based principal coordinate analysis
(PCoA) did not show clustering according to disease activity,
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IBD type, TNF-a inhibitor, aminosalicylate, prednisone or
methotrexate use (Figures S2, S3, S4). Age (R2 = 0.16;
p = 0.001), thiopurine use (R2 = 0.41; p = 0.001), gender
(R2= 0.35; p = 0.003), disease location of UC (R2= 0.34;
p = 0.008) were related to clustering (Figure 3 and Figure S1), as
tested by ANOSIM. For thiopurine use, Fusobacteria and
Verrucomicrobia phyla appeared to explain clustering for users,
whereas especially Lentisphaerae appeared to determine clustering
for non-users (Figure S5).
Table 1. Patient characteristicsa.
CD (n=10) UC (n=9)
Age (years) 42.5 (22–73) 65.0 (30–79)
Gender 6 =, 4 R 7 =, 2 R
Time since diagnosis (years) 7.5 (1–29) 10 (3–28)
Location 3 ileocolonicc 2 proctosigmoid
7 colonicc 5 left-sided
2 pancolitis
Medication use (n) b:
TNF-a inhibitor 7 1
Thiopurine 4 3
Aminosalicylate 1 4
Methotrexate 1 1
Prednisone 1 1
Calprotectin (mg/g feces):
- Remission 37.0 (17–82) 15.0 (15–115)
- Activity 365.0 (126–4,900) 231.0 (161–1,120)
Time between samples (remission to activity, in months) 1.5 (1–10) 3.0 (1–6)
aAge (year), calprotectin level (Calp) and time from remission to activity (months) displayed as median with the range in parentheses.
bNo change in IBD medication, except doubling of mesalazine in one patient (#5 in subsequent figures and text) and use of lactulose in another patient (#6) during
exacerbation.
cDisease extent in colon at time of inclusion was left-sided (n = 5), right sided (n = 2), pancolonic (n = 2) and cecal (n = 2).
doi:10.1371/journal.pone.0090981.t001
Figure 1. Relative abundance of bacterial phyla in fecal samples of nine UC (#1–9) and ten CD (#10–19) patients during remission
and subsequent exacerbation.
doi:10.1371/journal.pone.0090981.g001
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Unweighted UniFrac distances of patients were significantly
closer (p,0.001) between their own remission and exacerbation
samples than to samples of other patients (Figure 4). Only the
remission sample of patient #11 showed more similarity to the
other patients’ remission samples than to his own exacerbation
sample.
Interestingly, the mean distance in community membership
between paired Crohn’s disease samples (0.51; s.d. 0.12) was
significantly larger as compared to UC samples (0.42; s.d. 0.04;
p = 0.027). Using Bray-Curtis dissimilarity distances, the same
trend was observed with CD at 0.59 (s.d. 0.18) and UC at 0.42 (s.d.
0.09) (figure 5). This difference between the means was also
statistically significant as determined by Mann-Whitney U test
with p= 0.027.
Several associations were found between specific OTUs and
patient characteristics as determined by G-test and ANOVA, but
none of these withstood correction for multiple testing by means of
FDR (Tables S2, S3, S4, S5).
Discussion
To our knowledge, this is the first prospective study using next-
generation sequencing to examine the fecal microbiota composi-
tion in UC and CD during a quiescent disease phase and a
subsequent exacerbation.
Similar to previous studies on the human fecal microbiota, the
divisions of Firmicutes and Bacteroidetes predominated [42–44].
Although no overarching shifts in microbial communities could be
Table 2. Alpha-diversity metrics for IBD subtype, disease activity, 6-MP use (Median (range)).
Reads per sample Coverage (%) Observed OTUs Chao1 Shannon
CD 8,053.5 97,4 477.2 684.0 6.6
(6,503.0–10,033.0) (94.8–99.3) (72.1–652.8) (99.7–1087.6) (1.4–7.1)
UC 8,097.0 97.0 499.3 753.4 6.7
(6,194–11,030) (95.8–98.6) (272.7–675.7) (433.1–1047.3) (5.5–7.7)
Exacerbation 7,921.0 97.4 493.3 726.3 6.7
(6,194.0–11,030.0) (95.8–99.3) (72.1–664.5) (99.7–1087.6) (1.4–7.7)
Remission 8,169.0 97.0 493.9 747.7 6.6
(6,503.0–10,013.0) (94.8–99.1) (160.6–675.7) (308.9–1067.3) (2.8–7.4)
Thiopurine use 8,193.0 97.8 338.9 489.3 5.8
(6,465.0–10,013.0) (96.2–99.3) (72.1–517.4)a (99.7–868.4)a (1.4–7.0)b
No thiopurine
use
7,929.0 96.6 569.4 875.9 6.7
(6,194.0–11,030.0) (94.8–98.0) (406.9–675.7) (605.9–1087.6) (5.8–7.7)
asignificantly lower in thiopurine users, p,0.001.
bsignificantly lower in thiopurine users, p,0.01.
doi:10.1371/journal.pone.0090981.t002
Figure 2. Mean number of observed species (OTUs) according to thiopurine use in Crohn’s disease (p=2.57*1025), total
Inflammatory Bowel Disease (p=2.37*1024) and Ulcerative Colitis (p =7.93*1024) patients. *: Significantly different (p,0.001).
doi:10.1371/journal.pone.0090981.g002
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detected in the CD and UC populations, shifts in composition and
decreased diversity were observed in individual patients. More-
over, it was demonstrated that the microbiota within CD patients
was less stable compared to the microbiota from UC patients.
Finally, thiopurines appear to affect the gut microbial composition
and diversity.
In the present study, we were not able to identify overall
patterns in microbial changes related to the presence of an
exacerbation. An exacerbation was defined by endoscopic scores
and/or fecal calprotectin levels as indicators for mucosal
inflammation, as clinical scores are reported not to correlate very
well with endoscopy findings [32,33]. Mucosal inflammation is
increasingly recognized as outcome parameter for active disease
and is important for optimization of therapeutic strategies and to
prevent complications [45].
Previous studies did show microbial differences comparing
active with inactive IBD patients. For example, a combination of
leucocytes in the fecal-mucosal transition zone and the concen-
tration of F. prausnitzii were found to be strong predictors of active
CD and UC [7]. Diminished F. prausnitzii, as well as a lower
Firmicutes/Bacteroidetes ratio was also associated with active
disease in another study on 49 IBD patients [9]. Furthermore, a
decrease in the Clostridium family was found in active UC and
inactive and active CD compared to inactive UC and healthy
controls [20]. A decrease of C. coccoides, C. leptum subgroup,
Atophium cluster and B. ovatus was reported in feces of active
compared to inactive UC, [8] while increased counts of
bifidobacteria, E. coli and Clostridia were found in tissue specimens
of active compared to inactive UC by others [27].
The above-mentioned studies had a cross-sectional design and
are therefore more vulnerable to selection bias and confounding.
None of these studies did match patients with quiescent disease to
patients with active disease based on characteristics such as disease
location, medication, diet and other possible confounders, nor did
they adjust for these factors in their statistical analyses. In contrast,
two more recent studies that used pyrosequencing did not show
clustering based on disease status. A study by Willing et al. used a
multivariate statistical approach (partial least-squares discriminant
analysis) to distinguish disease phenotypes based on microbial
composition in 40 twin pairs [17]. Six patients had active disease
based on clinical scores, which could not be distinguished from 34
patients with inactive disease. In the second study, analyzing 231
biopsies and stool samples of IBD patients and healthy subjects,
disease activity was not associated with specific shifts in the
microbiome composition even after adjusting for other factors
such as sample type (i.e. stool or biopsy), IBD type, age, smoking
and medication [29].
A potential explanation for the lack of overarching shifts in
microbial composition at time of exacerbation in our study may be
due to the relatively small study population. Although we included
only CD patients with colonic disease and excluded IBD patients
with changes in medication over time, some heterogeneity in the
study population cannot be excluded. IBD can be considered a set
of diseases with overlapping phenotypes rather than a single
disease [46,47]. This may contribute to the patient-specific
Figure 3. Communities clustered using Principal Coordinates Analysis (PCoA) of the unweighted UniFrac distance matrix. (A) PC1
and PC2 are plotted on x- and y-axes. Each point corresponds to a community colored according to thiopurine use. All samples are shown. The
percentage of variation explained by the plotted principal coordinates is indicated on the axes. (B) PC1 and PC3 are plotted on x- and y-axis. Each
point corresponds to a community colored according to disease location. Only samples from UC patients are included.
doi:10.1371/journal.pone.0090981.g003
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microbial composition shifts, and lack thereof at group level. The
fact that from a large cohort of 323 subjects, only 19 fulfilled our
selection criteria, illustrates that it is very difficult to include a
rather large homogenous subpopulation.
The main strength of the present study is the prospective design
comparing the microbiota in association to disease activity within
the same patients followed over time, particularly considering the
interindividual differences in microbiota composition. Clear
subject-specific changes have been observed. As modifications of
medication use over time were not allowed, these changes were
most likely associated with the changing disease activity. Major
increases (up to 81.9%) in specific bacterial subspecies were
observed in five patients, being Lactobacillus spp. (in one UC
patient), B. dorei (in one UC patient), A. muciniphila (in one CD
patient), and B. fragilis (in two CD patients (#10 and #11)). These
two latter patients were both non-smoking females (age 35 and 50
years respectively) using a combination of thiopurines and TNF-
inhibitors continuously during the period of interest. Apart from
developing an exacerbation, no major changes in clinical or
environmental factors did occur during the follow-up period in any
of these patients that could have contributed to the observed
findings. Although larger patient numbers need to be studied
before final conclusions can be drawn on the role of the individual
commensal in the pathogenesis of IBD, the potential importance
of B. fragilis is supported by findings from others. B. fragilis was
found to be significantly more abundant in biopsies from CD
patients compared to UC patients and healthy subjects [23]. In
another study, the mucosal biofilm mass in IBD patients appeared
to be dominated by B. fragilis [24]. Some strains of B. fragilis are
enterotoxigenic by producing a zinc-dependent metalloprotease
toxin, and appear to be more prevalent in active IBD patients as
compared to inactive patients and control subjects [48]. Animal
models have confirmed that enterotoxigenic B. fragilis alone is
sufficient to induce colitis [49]. Furthermore, a potential role for
the eukaryotic-like ubiquitin gene in B. fragilis in the pathophys-
iology of CD has recently been postulated [50].
Figure 4. Within and between subjects pair-wise unweighted UniFrac distances for ulcerative colitis (#1–9) and Crohn’s disease
(#10–19) patients.
doi:10.1371/journal.pone.0090981.g004
Figure 5. Mean within subjects pair-wise Bray-Curtis distances
for ulcerative colitis and Crohn’s disease patients (p=0.027). *:
Significantly different (p,0.05).
doi:10.1371/journal.pone.0090981.g005
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In the present study, we found a different level of microbial
variability contributing to exacerbations in either CD or UC. This
may indicate that changes in gut bacterial composition play a
more important role in CD than in UC exacerbation develop-
ment. These findings are in line with findings by others. Willing
et al. (2010) found different microbial profiles between CD and
controls but not between UC and controls based on 454
sequencing [17]. In addition, Andoh et al. found inactive UC
patients to cluster with healthy controls, while inactive and active
CD clustered separately together with active UC [20].
Although the numbers were small, we found that thiopurine
treatment was associated with the microbial composition and the
diversity. Based upon the Principal Coordinate analysis, thiopur-
ine use was found to be the most important factor responsible for
clustering and was furthermore associated with a significant
decrease in alpha-diversity. It has previously been found that the
thiopurines 6-mercaptopurine (6-MP) and azathioprine inhibit
growth of M. avium subspecies paratuberculosis in vitro [51,52]. We
could not demonstrate an antimicrobial effect of 6-MP in vitro as
tested on Bacillus subtilis by disc diffusion test (test range 1–64 mg,
data not shown). This does however not exclude the possibility of
an (indirect) effect of 6-MP or one of its metabolites on the
intestinal microbiota in vivo.
As such, the present findings indicate that thiopurine use,
especially changes in administration or dosage over time, should
be considered as a potential confounding factor when studying the
microbiota composition in IBD. Replication of our findings on the
association between thiopurine use and shifts in microbiota
composition as well as more mechanistic insight on the potential
underlying mechanisms is warranted to prove a causal relation-
ship.
Conclusion
Although we did observe patient-specific shifts in microbial
composition, we could not demonstrate general changes in
microbial composition or diversity in IBD patients at time of
exacerbation as compared to a quiescent disease state. Patient-
specific shifts in fecal microbial composition seemed to be
associated with larger Bray-Curtis dissimilarity between remission
and active disease for CD as compared to UC. Furthermore,
thiopurine use was found to have significant impact on the
microbial composition and diversity, and should be considered
when studying the intestinal microbiota in relation to disease
course.
Larger prospective studies that enable controlling for potential
confounders such as medication, disease subtype and location, are
needed to unravel potential general shifts in the microbiota related
to exacerbations in IBD.
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